Your browser doesn't support javascript.
Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients.
Liontos, Michalis; Terpos, Evangelos; Kunadis, Elena; Zagouri, Flora; Briasoulis, Alexandros; Skafida, Efi; Fiste, Oraianthi; Markellos, Christos; Andrikopoulou, Angeliki; Gumeni, Sentiljana; Kaparelou, Maria; Koutsoukos, Konstantinos; Gavriatopoulou, Maria; Kastritis, Efstathios; Trougakos, Ioannis P; Dimopoulos, Meletios- Athanasios.
  • Liontos M; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece.
  • Terpos E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece.
  • Kunadis E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece.
  • Zagouri F; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece. florazagouri@yahoo.co.uk.
  • Briasoulis A; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece.
  • Skafida E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece.
  • Fiste O; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece.
  • Markellos C; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece.
  • Andrikopoulou A; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece.
  • Gumeni S; Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece.
  • Kaparelou M; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece.
  • Koutsoukos K; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece.
  • Gavriatopoulou M; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece.
  • Kastritis E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece.
  • Trougakos IP; Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece.
  • Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece.
Prostate Cancer Prostatic Dis ; 25(1): 117-118, 2022 03.
Article in English | MEDLINE | ID: covidwho-1461989
ABSTRACT
Data regarding the safety and efficacy of COVID-10 vaccines among cancer patients are lacking. Factors such as age, underlying disease and antineoplastic treatment confer negatively to the immune response due to vaccination. The degree of immunosuppression though may be lessen by targeted treatments like the androgen receptor-targeted agents (ARTA) that are commonly used in patients with metastatic prostate cancer. Herein, we report our data on 25 patients with prostate cancer under treatment with ARTA who were vaccinated for COVID-19. Our data suggest that these patients develop neutralizing antibodies against SARS-CoV-2 similarly to healthy volunteers. No safety issues were noted.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Prostatic Neoplasms, Castration-Resistant / COVID-19 / Antineoplastic Agents Type of study: Prognostic study Topics: Vaccines Limits: Humans / Male Language: English Journal: Prostate Cancer Prostatic Dis Journal subject: Endocrinology / Neoplasms / Urology Year: 2022 Document Type: Article Affiliation country: S41391-021-00455-9

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Prostatic Neoplasms, Castration-Resistant / COVID-19 / Antineoplastic Agents Type of study: Prognostic study Topics: Vaccines Limits: Humans / Male Language: English Journal: Prostate Cancer Prostatic Dis Journal subject: Endocrinology / Neoplasms / Urology Year: 2022 Document Type: Article Affiliation country: S41391-021-00455-9